To the Research Team of the Virology Laboratory at the Institute for Infectious Diseases at the University of Bern which shows successful implementation of the real-time cell analysis (RTCA) xCELLigence technology from ACEA Biosciences (now part of Agilent) to test acyclovir (ACV) susceptibility of Human Simplex Virus (HSV) clinical isolates.
OLS is happy to see that this method might help to adjust appropriate antiviral treatment for patients with refractory HSV infections and helping by getting faster and more efficient time to results!
Compared with other phenotypic methods, RTCA analysis requires less manipulation, reduces the workload and the turnaround time, and appears to be an objective and reliable method to test ACV susceptibility.
Publication: https://doi.org/10.1016/j.jcv.2020.104303; J Clin Virol . 2020 Feb 19;125:104303